This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Apr;12(4):315-6.

doi: 10.1016/S1470-2045(11)70074-2.

New combinations for mantle cell lymphoma: concerted action needed

Georg Hess¹

Affiliations

Affiliation

¹ Department of Hematology, Oncology, and Pneumology, Universitätsmedizin der Johannes Gutenberg-Universität, Langenbeckstr 1, 55131 Mainz, Germany. georg.hess@unimedizin-mainz.de

PMID: 21440504
DOI: 10.1016/S1470-2045(11)70074-2

Comment

New combinations for mantle cell lymphoma: concerted action needed

Georg Hess. Lancet Oncol. 2011 Apr.

. 2011 Apr;12(4):315-6.

doi: 10.1016/S1470-2045(11)70074-2.

Author

Georg Hess¹

Affiliation

¹ Department of Hematology, Oncology, and Pneumology, Universitätsmedizin der Johannes Gutenberg-Universität, Langenbeckstr 1, 55131 Mainz, Germany. georg.hess@unimedizin-mainz.de

PMID: 21440504
DOI: 10.1016/S1470-2045(11)70074-2

No abstract available

PubMed Disclaimer

Comment on

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.
Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE. Ansell SM, et al. Lancet Oncol. 2011 Apr;12(4):361-8. doi: 10.1016/S1470-2045(11)70062-6. Lancet Oncol. 2011. PMID: 21440503 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science